ArticleScientific reports2025
Comprehensive analysis of Mendelian randomization and scRNA-seq identify key prognostic genes and relevant functional roles in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The prognosis of advanced CRC is poor, and identifying key genes related to CRC is vital for improving CRC prognosis. Our research used univariate Cox analysis and Mendelian randomization (MR) analysis to identify key prognostic genes in CRC. Multiple datasets such as the nomogram model and single-cell sequencing (scRNA-seq) were used to investigate the potential molecular mechanisms of the key genes. The expression levels were confirmed by using quantitative real-time polymerase chain reaction (qRT-PCR). The biological functions and effect on prognosis of the identified prognostic genes were also explored. MMRN1 and SLC6A19 were identified as key prognostic genes for CRC. Subsequently, the nomogram model demonstrated that MMRN1 and SLC6A19 can strongly predict survival. Further examination with multiple datasets elucidated the potential molecular mechanisms of the key prognostic genes, revealing a close association with immune cell infiltration. MMRN1 is enriched in classic CRC signaling pathways, whereas SLC6A19 is enriched in metabolism-related pathways. They are closely linked to immune cell infiltration levels and significantly influence the immune microenvironment in CRC. These key prognostic genes are significantly correlated with chemotherapeutic drug sensitivity and present promising opportunities for CRC therapy. The expression of both key genes was also observed in the scRNA-seq data of CRC. Finally, qRT-PCR validation revealed that MMRN1 is markedly downregulated and SLC6A19 is significantly upregulated in CRC. Lower expression of MMRN1 and higher expression of SLC6A19 significantly promoted the proliferation and metastasis of colorectal cancer cells. Our study identified MMRN1 and SLC6A19 as potential key prognostic genes for CRC, as they can reliably predict the prognosis of CRC. Furthermore, the potential molecular mechanisms of MMRN1 and SLC6A19 were revealed, suggesting new drug targets and therapeutic directions for managing prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.